South Korean biopharmaceutical company GC Pharma (KRX:006280) announced on Friday its net income of KRW7.5bn for the three months ended 30 June 2021.

This marks an improvement of 46.0% when compared with the net income in the sake period in the prior year.

Revenues of KRW387.6bn were generated for the three months ended 30 June 2021, up 7.7% from KRW360.0bn in the second quarter of 2020. Despite in-licence vaccine products biz-out, the revenues growth of 0.2% was due to strong performance of local Rx and international Vx sales.

Operating profit of KRW11.1bn was recorded for the second quarter of 2021, down 28.8% from KRW15.6bn in the same period in 2020.

(USD1=KRW1,150.2313)